Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5333522 | 1.00 | HSPB1 (0.36) | HSPB1TDP2PKMGAAL3MBTL1 | |
| SCHEMBL5338153 | 0.92 | HSPB1 (0.36) | HSPB1TDP2GAAL3MBTL1ALDH1A1 | |
| SCHEMBL4500711 | 0.92 | HSPB1 (0.36) | HSPB1TDP2GAAL3MBTL1ALDH1A1 | |
| SCHEMBL4497632 | 0.92 | HSPB1 (0.37) | HSPB1TDP2PKMGAAL3MBTL1 | |
| SCHEMBL5333924 | 0.92 | HSPB1 (0.37) | HSPB1TDP2PKMGAAL3MBTL1 | |
| SCHEMBL4229234 | 0.91 | HSPB1 (0.35) | HSPB1TDP2PKMGAAL3MBTL1 | |
| SCHEMBL5334888 | 0.90 | PKM (0.36) | HSPB1PKMGAAL3MBTL1ALDH1A1 | |
| SCHEMBL4512824 | 0.90 | PKM (0.36) | HSPB1PKMGAAL3MBTL1ALDH1A1 | |
| SCHEMBL4506374 | 0.87 | SCN9A (0.33) | L3MBTL1LMNAMAPTKDM4C | |
| SCHEMBL5329457 | 0.87 | SCN9A (0.33) | L3MBTL1LMNAMAPTKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | claimed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| WO-2007029062-A2 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | CYP3A4, CYP4B1, CYP3A5 | HSPB1 4828/4885TDP2 3419/4885PKM 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.